Drug intelligence / Profile preview

GNRs@Chit-Iso4

Development stage: Preclinical
Lead developer: IRCCS Ospedale San Raffaele
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravesical

Overview

**GNRs@Chit-Iso4** is a preclinical, intravesically administered photoacoustic imaging nanosystem for early detection of bladder cancer. It consists of gold nanorods coated with chitosan and functionalized with the head-to-tail cyclized Iso4 peptide, which selectively binds integrin alpha-5/beta-1 expressed on bladder cancer cells. Following bladder instillation and low-frequency ultrasound-assisted nanoparticle dispersion, the targeted gold nanorods generate photoacoustic contrast that enabled detection of orthotopic bladder lesions smaller than 0.5 mm in murine models. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S2213597922000659))

Other names: GNRs@Chit-Iso4

Targets

ITGA5:ITGB1 (Integrin α5β1)

Beyond the preview

Go deeper on GNRs@Chit-Iso4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GNRs@Chit-Iso4.

Explore the full profile